Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

468.85 -10.68 (-2.23%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
62 63 Next >
3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow
Vertex should have a future full of bright tomorrows. 
Via The Motley Fool
Vertex Pharmaceuticals's Options Frenzy: What You Need to Know
Via Benzinga
Biotech And Life Science Sector Update Summer Of 2024
It’s the slowest week of the year, we are at the market top and most earnings reports are good. 
Via Talk Markets
Jim Cramer: 'Hold On' To Builders FirstSource, 'Here's The Problem' With Viking Therapeutics
Jim Cramer discusses Serve Robotics, Builders FirstSource, Vertex Pharmaceuticals and Viking Therapeutics on CNBC. 
Via Benzinga
Looking Into Vertex Pharmaceuticals's Recent Short Interest
Via Benzinga
Unpacking the Latest Options Trading Trends in Vertex Pharmaceuticals
Via Benzinga
If You Invested $100 In This Stock 20 Years Ago, You Would Have $4,900 Today
Via Benzinga
Unpacking the Latest Options Trading Trends in Vertex Pharmaceuticals
Via Benzinga
Forget Novo Nordisk: Buy This Magnificent Pharma Stock Instead
Vertex Pharmaceuticals has a lot going for it. 
Via The Motley Fool
Vertex to Participate in Upcoming September Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Biotech Bull Market: 3 Ways To Play It
Although we are in the later stages of this bull market a cut in interest rates by the Fed should help biotech as you have seen from the recent rally. 
Via Talk Markets
Topics Economy
Soviet Code Breaker Jim Simons' Hedge Fund Renaissance Technologies — Ozempic, Wegovy Maker Novo Nordisk Along With Nvidia, Palantir Among Top Holdings
Renaissance Technologies, the hedge fund founded by legendary mathematician and former NSA code breaker Jim Simons, recently disclosed its latest stock holdings in a 13F filing with the U.S. Securities... 
Via Benzinga
These 2 Incredible Growth Stocks Are Set to Soar This Summer and Beyond
It's always a good time to invest cash in quality businesses. 
Via The Motley Fool
3 Fantastic Growth Stocks to Buy in August
These stocks should keep up their winning ways. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 Biotech Stocks to Buy on the Dip: August 2024
These are three of the best biotech stocks to buy on the dip due to their strong fundamentals and market positioning. 
Via InvestorPlace
Prediction: These 4 Future Technologies Will Be Millionaire-Makers -- and Here Are the Top Stocks to Buy Now to Profit From Them
These technologies could be game-changers. And they could make forward-thinking investors a lot of money. 
Via The Motley Fool
2 Biotech Stocks to Buy Hand Over Fist in August
Both of these biotechs are highly innovative companies. 
Via The Motley Fool
The 3 Best Biotech Stocks to Buy in August 2024
These biotech stocks are leading the way with groundbreaking therapies and robust fundamentals offering superb upside ahead. 
Via InvestorPlace
Vertex Announces CASGEVY™ Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia in England
From Vertex Pharmaceuticals
Via Business Wire
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
Shares of the rare disease drugmaker are already up more than 40% over the past year. 
Via The Motley Fool
Prediction: These Could Be the Best-Performing Growth Stocks Through 2030
Great companies are found in every type of market landscape. 
Via The Motley Fool
3 Biotech Stocks on Track for 50% Returns (or More) by 2028
Investors should consider snapping up these high potential biotech stocks that could return 50% or more by 2028! 
Via InvestorPlace
Prediction: CRISPR Therapeutics Stock Could Be a Millionaire-Maker
The biotech recently became a commercial-stage company. 
Via The Motley Fool
3 Unstoppable Stocks to Buy in August
It's not hard to envision how all three of these stocks can deliver exceptional growth. 
Via The Motley Fool
Prediction: 2 Stocks That Will Be Worth More Than Johnson & Johnson 10 Years From Now
These two healthcare companies have far more upside potential than Johnson & Johnson. 
Via The Motley Fool
3 Biotech Stocks That Could Have Investors Grinning Soon
Biotech stocks are a high risk, high reward investment and these three biotechs offer significant upside potential. 
Via InvestorPlace
Magnificent 7 Lose Over $300B As Volatility Index Surges, Traders Question Fed's Timing: What's Driving Markets Friday?
Wall Street is experiencing a sharp decline on the last trading day of the week, with all indices in the red at noon in New York, as a cooler-than-expected July jobs report rattled risk sentiment and... 
Via Benzinga
Topics Economy
Vertex Pharmaceuticals Lifts Annual Guidance, Positive Growth For Its Cystic Fibrosis Franchise And Pain Management Pipeline
Vertex Pharmaceuticals reported Q2 revenues of $2.65B, near the $2.66B estimate, with an adjusted EPS loss of $(12.83), missing the $4.14 consensus. The analyst expects strong growth in the pain... 
Via Benzinga
Should Investors Worry About Vertex Pharmaceuticals $3.6 Billion Q2 Loss? Not Even for a Second.
Vertex's first loss in years is a big nothingburger. 
Via The Motley Fool
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
62 63 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.